Skip to main content
Top
Published in: Medical Microbiology and Immunology 2/2020

01-04-2020 | Original Investigation

Alternative pathway of complement activation has a beneficial role against Chandipura virus infection

Authors: Pooja Gupta, Anuradha S. Tripathy

Published in: Medical Microbiology and Immunology | Issue 2/2020

Login to get access

Abstract

The complement system is a critical component of both innate and adaptive immune responses. It has both protective and pathogenic roles in viral infections. There are no studies regarding the role of complement system in Chandipura virus (CHPV) infection. The current study has investigated the role of complement pathways in the in vitro neutralization of CHPV in Vero E6 cells. Using normal human serum (NHS), heat-inactivated serum (HIS), human serum deficient of complement factor, respective reconstituted serum, assays like in vitro neutralization, real-time PCR, and flow cytometry-based tissue culture-based limited dose assay (TC-LDA) were carried out for assessing the activation of different complement pathways. NHS from 9/10 donors showed complement dependent neutralization, reduction in viral load and decrease in percentage of CHPV-positive cells compared to their HIS counterparts. EGTA or EDTA pretreatment experiments indicated that CHPV neutralization proceeds through the alternative pathway of the complement activation. Our data showed a strong dependence on C3 for the in vitro neutralization of CHPV. Disparity in CHPV neutralization levels between factor B-deficient and reconstituted sera could be attributed to amplification loop/“tick-over” mechanism. Assays using C3, C5, and C8 deficient sera indicated that complement-mediated CHPV neutralization and suppression of CHPV infectivity are primarily through C3 and C5, and not dependent on downstream complement factor C8. With no specific anti-viral treatment/vaccine against Chandipura, the current data, elucidating role of human complement system in the neutralization of CHPV, may help in designing effective therapeutics.
Literature
1.
go back to reference Bhatt PN, Rodrigues FM (1967) Chandipura: a new arbovirus isolated in India from patients with febrile illness. Indian J Med Res 55:1295–1305PubMed Bhatt PN, Rodrigues FM (1967) Chandipura: a new arbovirus isolated in India from patients with febrile illness. Indian J Med Res 55:1295–1305PubMed
2.
go back to reference Rao BL, Basu A, Wairagkar NS, Gore MM, Arankalle VA, Thakare JP, Jadi RS, Rao KA, Mishra AC (2004) A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 364:869–874PubMed Rao BL, Basu A, Wairagkar NS, Gore MM, Arankalle VA, Thakare JP, Jadi RS, Rao KA, Mishra AC (2004) A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 364:869–874PubMed
3.
go back to reference Tandale BV, Tikute SS, Arankalle VA, Sathe PS, Joshi MV, Ranadive SN, Kanojia PC, Eshwarachary D, Kumarswamy M, Mishra AC (2004) Chandipura virus: a major cause of acute encephalitis in children in north Telangana, Andhra Pradesh, India. J Med Virol 80:118–124 Tandale BV, Tikute SS, Arankalle VA, Sathe PS, Joshi MV, Ranadive SN, Kanojia PC, Eshwarachary D, Kumarswamy M, Mishra AC (2004) Chandipura virus: a major cause of acute encephalitis in children in north Telangana, Andhra Pradesh, India. J Med Virol 80:118–124
4.
go back to reference Chadha MS, Arankalle VA, Jadi RS, Joshi MV, Thakare JP, Mahadev PV, Mishra AC (2005) An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat State, India. Am J Trop Med Hyg 73:566–570PubMed Chadha MS, Arankalle VA, Jadi RS, Joshi MV, Thakare JP, Mahadev PV, Mishra AC (2005) An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat State, India. Am J Trop Med Hyg 73:566–570PubMed
5.
go back to reference Gurav YK, Tandale BV, Jadi RS, Gunjikar RS, Tikute SS, Jamgaonkar AV (2010) Chandipura virus encephalitis outbreak among children in Nagpur division, Maharashtra, 2007. Indian J Med Res 132:395–399PubMed Gurav YK, Tandale BV, Jadi RS, Gunjikar RS, Tikute SS, Jamgaonkar AV (2010) Chandipura virus encephalitis outbreak among children in Nagpur division, Maharashtra, 2007. Indian J Med Res 132:395–399PubMed
6.
go back to reference Dwibedi B, Sabat J, Hazra RK, Kumar A, Dinesh DS, Kar SK (2015) Chandipura virus infection causing encephalitis in a tribal population of Odisha in eastern India. Natl Med J India 28:185–187PubMed Dwibedi B, Sabat J, Hazra RK, Kumar A, Dinesh DS, Kar SK (2015) Chandipura virus infection causing encephalitis in a tribal population of Odisha in eastern India. Natl Med J India 28:185–187PubMed
7.
go back to reference Basak S, Mondal A, Polley S, Mukhopadhyay S, Chattopadhyay D (2007) Reviewing Chandipura: a vesiculovirus in human epidemics. Biosci Rep 27:275–298PubMedPubMedCentral Basak S, Mondal A, Polley S, Mukhopadhyay S, Chattopadhyay D (2007) Reviewing Chandipura: a vesiculovirus in human epidemics. Biosci Rep 27:275–298PubMedPubMedCentral
8.
go back to reference Rao NS, Wairagkar NS, Mohan MV, Khetan M, Somavathi S (2008) Brain stem encephalitis associated with Chandipura virus in Andhra Pradesh outbreak. J Trop Pediatr 54:25–30 Rao NS, Wairagkar NS, Mohan MV, Khetan M, Somavathi S (2008) Brain stem encephalitis associated with Chandipura virus in Andhra Pradesh outbreak. J Trop Pediatr 54:25–30
9.
go back to reference Venkateswarlu CH, Arankalle VA (2009) Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine 27:2845–2850PubMed Venkateswarlu CH, Arankalle VA (2009) Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine 27:2845–2850PubMed
10.
go back to reference Ghosh S, Basu A (2017) Neuropathogenesis by Chandipura virus: an acute encephalitis syndrome in India. Natl Med J India 30:21–25PubMed Ghosh S, Basu A (2017) Neuropathogenesis by Chandipura virus: an acute encephalitis syndrome in India. Natl Med J India 30:21–25PubMed
11.
go back to reference Kumar S, Arankalle VA (2010) Intracranial administration of P gene siRNA protects mice from lethal Chandipura virus encephalitis. PLoS One 5:1–13 Kumar S, Arankalle VA (2010) Intracranial administration of P gene siRNA protects mice from lethal Chandipura virus encephalitis. PLoS One 5:1–13
12.
go back to reference Roy A, Chakraborty P, Polley S, Chattopadhyay D, Roy S (2013) A peptide targeted against phosphoprotein and leader RNA interaction inhibits growth of Chandipura virus—an emerging Rhabdovirus. Antivir Res 100:346–355PubMed Roy A, Chakraborty P, Polley S, Chattopadhyay D, Roy S (2013) A peptide targeted against phosphoprotein and leader RNA interaction inhibits growth of Chandipura virus—an emerging Rhabdovirus. Antivir Res 100:346–355PubMed
13.
go back to reference Venkateswarlu CH, Arankalle VA (2010) Evaluation of the immunogenicity of a recombinant glycoprotein-based Chandipura vaccine in combination with commercially available DPT vaccine. Vaccine 28:1463–1467PubMed Venkateswarlu CH, Arankalle VA (2010) Evaluation of the immunogenicity of a recombinant glycoprotein-based Chandipura vaccine in combination with commercially available DPT vaccine. Vaccine 28:1463–1467PubMed
14.
go back to reference Jadi RS, Anakkathil SB, Barde PV, Arankalle VA, Mishra AC (2011) Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: vesiculovirus). Vaccine 29:4613–4617PubMed Jadi RS, Anakkathil SB, Barde PV, Arankalle VA, Mishra AC (2011) Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: vesiculovirus). Vaccine 29:4613–4617PubMed
15.
go back to reference Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7:9–18PubMed Kemper C, Atkinson JP (2007) T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7:9–18PubMed
16.
go back to reference Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981–986PubMed Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981–986PubMed
17.
go back to reference Blue CE, Spiller OB, Blackbourn DJ (2004) The relevance of complement to virus biology. Virology 319:176–184PubMed Blue CE, Spiller OB, Blackbourn DJ (2004) The relevance of complement to virus biology. Virology 319:176–184PubMed
18.
go back to reference Gasque P (2004) Complement: a unique innate immune sensor for danger signals. Mol Immunol 41:1089–1098PubMed Gasque P (2004) Complement: a unique innate immune sensor for danger signals. Mol Immunol 41:1089–1098PubMed
19.
go back to reference Johnson JB, Grant K, Parks GD (2009) The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 To evade complement-mediated neutralization. J Virol 83:7602–7611PubMedPubMedCentral Johnson JB, Grant K, Parks GD (2009) The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 To evade complement-mediated neutralization. J Virol 83:7602–7611PubMedPubMedCentral
20.
go back to reference Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058–1066PubMed Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058–1066PubMed
21.
go back to reference Stahl PD, Ezekowitz RA (1998) The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 10:50–55PubMed Stahl PD, Ezekowitz RA (1998) The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 10:50–55PubMed
22.
go back to reference Lu J, Le Y (1998) Ficolins and the fibrinogen like domain. Immunobiology 199:190–199PubMed Lu J, Le Y (1998) Ficolins and the fibrinogen like domain. Immunobiology 199:190–199PubMed
23.
go back to reference Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative pathway: acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 154:856–867PubMed Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative pathway: acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 154:856–867PubMed
25.
go back to reference Biswas M, Johnson JB, Kumar SRP, Parks GD, Subbiaha E (2012) Incorporation of host complement regulatory proteins into newcastle disease virus enhances complement evasion. J Virol 86:12708PubMedPubMedCentral Biswas M, Johnson JB, Kumar SRP, Parks GD, Subbiaha E (2012) Incorporation of host complement regulatory proteins into newcastle disease virus enhances complement evasion. J Virol 86:12708PubMedPubMedCentral
26.
go back to reference Balakrishnan A, Mishra AC (2008) Immune response during acute Chandipura viral infection in experimentally infected susceptible mice. Virol J 5:121PubMedPubMedCentral Balakrishnan A, Mishra AC (2008) Immune response during acute Chandipura viral infection in experimentally infected susceptible mice. Virol J 5:121PubMedPubMedCentral
27.
go back to reference Balakrishnan A, Shahir P (2011) Immune regulation in Chandipura virus infection: characterization of CD4+ T regulatory cells from infected mice. Virol J 8:259 Balakrishnan A, Shahir P (2011) Immune regulation in Chandipura virus infection: characterization of CD4+ T regulatory cells from infected mice. Virol J 8:259
28.
go back to reference Balakrishnan A, Shahir P (2012) Chandipura Virus infection in mice: the role of toll like receptor 4 in pathogenesis. BMC Infect Dis 12:125 Balakrishnan A, Shahir P (2012) Chandipura Virus infection in mice: the role of toll like receptor 4 in pathogenesis. BMC Infect Dis 12:125
29.
go back to reference Balakrishnan A, Balasubramaniam GA, Shelke VN, Gunjikar R, Shewale P (2013) Neuro-invasion of Chandipura virus mediates pathogenesis in experimentally infected mice. Int J Clin Exp Pathol 6:1272–1281 Balakrishnan A, Balasubramaniam GA, Shelke VN, Gunjikar R, Shewale P (2013) Neuro-invasion of Chandipura virus mediates pathogenesis in experimentally infected mice. Int J Clin Exp Pathol 6:1272–1281
30.
go back to reference Roy S, Pavitrakar D, Gunjikar R, Ayachit VM, Bondre VP, Sapkal GN (2016) Monocytes and B cells support active replication of Chandipura virus. BMC Infect Dis 16:487PubMedPubMedCentral Roy S, Pavitrakar D, Gunjikar R, Ayachit VM, Bondre VP, Sapkal GN (2016) Monocytes and B cells support active replication of Chandipura virus. BMC Infect Dis 16:487PubMedPubMedCentral
31.
go back to reference Beebe DP, Cooper NR (1981) Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol 126:1562–1568PubMed Beebe DP, Cooper NR (1981) Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol 126:1562–1568PubMed
32.
go back to reference Reed JL, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497 Reed JL, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497
33.
go back to reference Johnson JB, Capraro GA, Parks GD (2008) Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses Simian virus 5 and Mumps virus. Virology 376:112–123PubMedPubMedCentral Johnson JB, Capraro GA, Parks GD (2008) Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses Simian virus 5 and Mumps virus. Virology 376:112–123PubMedPubMedCentral
35.
go back to reference Parasha D, Paingankar Mandar S, Kumar Satyendra, Gokhale Mangesh D, Sudeep AB, Shinde Sapana B, Arankalle VA (2013) Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis 7(9):e2405 Parasha D, Paingankar Mandar S, Kumar Satyendra, Gokhale Mangesh D, Sudeep AB, Shinde Sapana B, Arankalle VA (2013) Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis 7(9):e2405
36.
go back to reference Des Prez RM, Bryan CS, Hawiger J, Colley DG (1975) Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-Ethylene glycol tetraacetic acid. Infect Immun 11:1235–1243PubMedPubMedCentral Des Prez RM, Bryan CS, Hawiger J, Colley DG (1975) Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-Ethylene glycol tetraacetic acid. Infect Immun 11:1235–1243PubMedPubMedCentral
37.
go back to reference Kumar S, Jadi RS, Anakkathil SB, Tandale BV, Mishra AC, Arankalle VA (2008) Development and evaluation of a real-time one step Reverse-Transcriptase PCR for quantitation of Chandipura Virus. BMC Infect Dis 8:168PubMedPubMedCentral Kumar S, Jadi RS, Anakkathil SB, Tandale BV, Mishra AC, Arankalle VA (2008) Development and evaluation of a real-time one step Reverse-Transcriptase PCR for quantitation of Chandipura Virus. BMC Infect Dis 8:168PubMedPubMedCentral
38.
go back to reference Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PVL (2009) Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27:2513–2522PubMed Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PVL (2009) Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27:2513–2522PubMed
39.
go back to reference Kumar M, Anakkathil SB, Arankalle VA (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30:6142–6149PubMed Kumar M, Anakkathil SB, Arankalle VA (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30:6142–6149PubMed
40.
go back to reference Hammarlund E, Amanna IJ, Dubois ME, Barron A, Engelmann F (2012) A flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus. PLoS One 7:e41707PubMedPubMedCentral Hammarlund E, Amanna IJ, Dubois ME, Barron A, Engelmann F (2012) A flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus. PLoS One 7:e41707PubMedPubMedCentral
41.
go back to reference Johnson JB, Aguilar HC, Lee B, Parks GD (2011) Interactions of human complement with virus particles containing the Nipah virus glycoproteins. J Virol 85:5940–5948PubMedPubMedCentral Johnson JB, Aguilar HC, Lee B, Parks GD (2011) Interactions of human complement with virus particles containing the Nipah virus glycoproteins. J Virol 85:5940–5948PubMedPubMedCentral
42.
go back to reference Ochsenbein AF, Pinschewer DD, Odermatt B, Carroll MC, Hengartner H, Zinkernagel RM (1999) Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med 190:1165–1174PubMedPubMedCentral Ochsenbein AF, Pinschewer DD, Odermatt B, Carroll MC, Hengartner H, Zinkernagel RM (1999) Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med 190:1165–1174PubMedPubMedCentral
43.
go back to reference Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ (2014) Vesiculovirus neutralization by natural IgM and complement. J Virol 88:6148–6157PubMedPubMedCentral Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ (2014) Vesiculovirus neutralization by natural IgM and complement. J Virol 88:6148–6157PubMedPubMedCentral
44.
go back to reference Hirsch RL, Winkelstein JA, Griffin DE (1980) The role of complement in viral infections III. Activation of the classical and alternative complement pathways by Sindbis virus. J Immunol 124:2507–2510PubMed Hirsch RL, Winkelstein JA, Griffin DE (1980) The role of complement in viral infections III. Activation of the classical and alternative complement pathways by Sindbis virus. J Immunol 124:2507–2510PubMed
45.
go back to reference Shuang Hu, Kumar Dipu Mohan, Sax Chelsea, Schuler Clayton, Akkina Ramesh (2016) Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses. Virology 488:162–168 Shuang Hu, Kumar Dipu Mohan, Sax Chelsea, Schuler Clayton, Akkina Ramesh (2016) Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses. Virology 488:162–168
46.
go back to reference Mills BJ, Beebe DP, Cooper NR (1979) Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol 121:1549–1557 Mills BJ, Beebe DP, Cooper NR (1979) Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol 121:1549–1557
47.
48.
go back to reference Sahu A, Lambris JD (2001) Structure and biology of complement C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35–48PubMed Sahu A, Lambris JD (2001) Structure and biology of complement C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35–48PubMed
49.
go back to reference Harrison RA (2018) The properdin pathway: an “alternative activation pathway” or a “critical amplification loop” for C3 and C5 activation? Semin Immunopathol 40:15–35PubMed Harrison RA (2018) The properdin pathway: an “alternative activation pathway” or a “critical amplification loop” for C3 and C5 activation? Semin Immunopathol 40:15–35PubMed
50.
go back to reference Pangburn MK, Müller-Eberhard HJ (1986) The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 235:723–730PubMedPubMedCentral Pangburn MK, Müller-Eberhard HJ (1986) The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 235:723–730PubMedPubMedCentral
51.
go back to reference Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370–2379PubMed Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370–2379PubMed
52.
go back to reference Nilsson B, Nilsson Ekdahl K (2012) The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 217:1106–1110PubMed Nilsson B, Nilsson Ekdahl K (2012) The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology 217:1106–1110PubMed
53.
go back to reference Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD (2017) Gros P Regulator dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat Struct Mol Biol 24:643–651PubMedPubMedCentral Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD (2017) Gros P Regulator dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat Struct Mol Biol 24:643–651PubMedPubMedCentral
54.
go back to reference Thurman JM, Holers VM (2006) The central role of the alternative complement pathway in human disease. J Immunol 176:1305–1310PubMed Thurman JM, Holers VM (2006) The central role of the alternative complement pathway in human disease. J Immunol 176:1305–1310PubMed
55.
go back to reference Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE (2004) The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 138:439–446PubMedPubMedCentral Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE (2004) The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 138:439–446PubMedPubMedCentral
56.
go back to reference Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP (2007) Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol 179:4101–4109PubMed Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP (2007) Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol 179:4101–4109PubMed
57.
go back to reference Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part I—molecular mechanisms of activation and regulation. Front Immunol 6:262PubMedPubMedCentral Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part I—molecular mechanisms of activation and regulation. Front Immunol 6:262PubMedPubMedCentral
58.
go back to reference Friedman HM, Wang L, Pangburn MK, Lambris JD, Lubinski J (2000) Novel mechanism of antibody independent complement neutralization of Herpes Simplex virus type 1. J Immunol 165:4528–4536PubMed Friedman HM, Wang L, Pangburn MK, Lambris JD, Lubinski J (2000) Novel mechanism of antibody independent complement neutralization of Herpes Simplex virus type 1. J Immunol 165:4528–4536PubMed
59.
go back to reference Bartholomew RM, Esser AF, Muller-Eberhard HJ (1978) Lysis of oncornaviruses by human serum Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 147:844–853PubMed Bartholomew RM, Esser AF, Muller-Eberhard HJ (1978) Lysis of oncornaviruses by human serum Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 147:844–853PubMed
60.
go back to reference Cooper NR, Jensen FC, Welsh RM Jr, Oldstone MB (1976) MBA Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 44:970–984 Cooper NR, Jensen FC, Welsh RM Jr, Oldstone MB (1976) MBA Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 44:970–984
61.
go back to reference Mills BJ, Beebe DP, Cooper NR (1979) Antibody-independent neutralization of vesicular stomatitis virus by human complement II Formation of VSV lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol 123:2518PubMed Mills BJ, Beebe DP, Cooper NR (1979) Antibody-independent neutralization of vesicular stomatitis virus by human complement II Formation of VSV lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol 123:2518PubMed
62.
go back to reference Oldstone MBA, Cooper NR, Larson DL (1974) Formation and biologic role of polyoma virus-antibody complexes A critical role for complement. J Exp Med 1974(140):549–565 Oldstone MBA, Cooper NR, Larson DL (1974) Formation and biologic role of polyoma virus-antibody complexes A critical role for complement. J Exp Med 1974(140):549–565
63.
go back to reference Beebe DP, Cooper NR (1981) Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol 126:1562–1568PubMed Beebe DP, Cooper NR (1981) Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol 126:1562–1568PubMed
Metadata
Title
Alternative pathway of complement activation has a beneficial role against Chandipura virus infection
Authors
Pooja Gupta
Anuradha S. Tripathy
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2020
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-019-00648-z

Other articles of this Issue 2/2020

Medical Microbiology and Immunology 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.